

## **Supplemental Table of Contents**

Supplemental Table 1. Univariate and multivariable analysis by logistic regression on factors associated with acute kidney injury in patients infected by SARS-CoV and SARS-CoV-2.

Supplemental Table 2. Univariate and multivariable analysis by logistic regression on factors associated with primary endpoint (a composite endpoint of admission to intensive care unit, use of invasive mechanical ventilation, and death) in 214 and 66 patients infected by SARS-CoV and SARS-CoV-2 with AKI, respectively.

Supplemental Table 1. Univariate and multivariable analysis by logistic regression on factors associated with acute kidney injury in patients infected by SARS-CoV and SARS-CoV-2.

Parameters	Univariate analysis		Multivariable analysis	
	OR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
<b>COVID-19 vs. SARS*</b>	0.56 (0.42 – 0.74)	<0.001	0.85 (0.62 – 1.16)	0.300
<b>Age</b>	1.05 (1.04 – 1.06)	<0.001	1.03 (1.02 – 1.04)	<0.001
<b>Male gender</b>	1.57 (1.22 – 2.02)	<0.001		
<b>Diabetes mellitus</b>	4.64 (3.51 – 6.13)	<0.001	1.94 (1.41 – 2.67)	<0.001
<b>Hypertension</b>	5.41 (4.16 – 7.03)	<0.001	1.67 (1.19 – 2.34)	0.003
<b>Use of antiviral agents</b>	1.71 (1.07 – 2.71)	0.024	1.80 (1.08 – 3.01)	0.025
<b>Use of corticosteroid</b>	1.33 (1.02 – 1.73)	0.034		
<b>Baseline creatinine</b>	1.02 (1.01 – 1.02)	<0.001	1.01 (1.00 – 1.01)	<0.001

20 patients who received renal replacement therapy at diagnosis of SARS-CoV were not included in the analysis.

*P* value = 0.710 for Hosmer-Lemeshow goodness-of-fit test, which did not indicate significant poor fit.

\* The factor COVID-19 vs. SARS was forced into the model.

aOR = adjusted odds ratio; CI = confidence interval; CoV = coronavirus; COVID-19 = coronavirus disease 2019; SARS = severe acute respiratory syndrome.

Supplemental Table 2. Univariate and multivariable analysis by logistic regression on factors associated with primary endpoint (a composite endpoint of admission to intensive care unit, use of invasive mechanical ventilation, and death) in 214 and 66 patients infected by SARS-CoV and SARS-CoV-2 with AKI, respectively.

Parameters	Univariate analysis		Multivariable analysis <sup>#</sup>	
	OR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
<b>COVID-19 vs. SARS</b>	0.12 (0.06 – 0.23)	<0.001	0.11 (0.05 – 0.25)	<0.001
<b>Age</b>	1.02 (1.00 – 1.03)	0.009		
<b>Male gender</b>	1.99 (1.23 – 3.22)	0.005	2.46 (1.30 – 4.66)	0.006
<b>Diabetes mellitus</b>	3.38 (1.97 – 5.79)	<0.001	3.13 (1.63 – 6.01)	0.001
<b>Hypertension</b>	2.20 (1.36 – 3.58)	0.001		
<b>Lymphocyte &lt;1x10<sup>9</sup>/L</b>	1.86 (1.15 – 3.01)	0.012		
<b>Platelet &lt;100x10<sup>9</sup>/L</b>	10.05 (1.30 – 77.96)	0.027		
<b>Peak ALT and/or AST ≥80 U/L</b>	3.13 (1.91 – 5.16)	<0.001	1.92 (1.03 – 3.58)	0.041
<b>Acute kidney injury</b>				
<b>AKI stage 1</b>	Reference		Reference	
<b>AKI stage 2</b>	7.12 (2.82 – 17.99)	<0.001	4.99 (1.81 – 13.70)	0.002
<b>AKI stage 3</b>	12.21 (5.28 – 28.23)	<0.001	9.66 (3.87 – 24.12)	<0.001

20 patients who received renal replacement therapy at diagnosis of SARS-CoV were not included in the analysis.

<sup>#</sup> *P* value = 0.331 for Hosmer-Lemeshow goodness-of-fit test, which did not indicate significant poor fit.

aOR = adjusted odds ratio; CI = confidence interval; CoV = coronavirus; COVID-19 = coronavirus disease 2019; SARS = severe acute respiratory syndrome.